[{'Name': 'AC Immune SA', 'Country': 'Switzerland', 'Ticker': 'ACIU', 'Sector': 'Healthcare', 'Business Type': 'Biotechnology', 'Business Model': 'Biotechnology'}, {'Pre-Tax Income': [13.356, -9.353], 'Net Interest Income': [0.285, -1.09], 'Return on Assets %': [58.87, -27.54], 'Purchase Of Property, Plant, Equipment': [-0.1, -0.314], 'Book Value per Share': [1.686, 2.712], 'Return on Equity %': [67.07, -30.71], 'Cash Flow from Financing': [13.963, 69.975], 'DeferredTaxAndRevenue': [2.16, 1.342], 'Total Liabilities': [13.141, 14.873], 'Additional Paid-In Capital': [127.26, 193.172], '  Net Income': [13.356, -9.354], '  Current Deferred Revenue': [2.16, 1.342], 'Research & Development': [5.824, 7.908], 'Sloan Ratio (%)': [0.9, -1.84], 'Earnings Yield (Joel Greenblatt)': [0.0, -0.89], 'Days Sales Outstanding': [71.66, 59.69], 'Operating Income': [12.859, -8.298], 'EPS (Diluted)': [0.129, -0.185], 'Gross Profit to Total Asset %': [90.77, 4.03], 'Operating Margin %': [62.45, -605.85], 'Quick Ratio': [10.74, 14.5], 'Enterprise Value': [0.0, 750.506], 'eps without NRI': [0.134, -0.185], 'Revenue': [20.592, 1.37], 'Other Current Assets': [4.615, 1.253], 'EV-to-EBITDA': [0.0, -117.27], 'Net Cash (per share)': [1.3, 2.65], 'Accounts Payable & Accrued Expense': [7.575, 9.864], 'PensionAndRetirementBenefit': [3.297, 3.557], 'Stock Based Compensation': [0.113, 0.206], 'FCF Margin %': [1.93, 612.75], 'Other Income (Expense)': [0.212, 0.036], '  Change In Receivables': [-14.463, 15.214], 'PS Ratio': [0.0, 39.78], 'Return on Capital  - Joel Greenblatt %': [850.87, -525.81], 'Property, Plant and Equipment': [0.689, 0.94], 'Net Income From Continuing Operations': [13.356, -9.354], 'Capital Expenditure': [-0.1, -0.314], 'Shares Outstanding (Diluted Average)': [55.396, 51.479], 'EBITDA': [13.15, -8.202], 'Total Equity to Total Asset': [0.877, 0.91], 'Net Income (Continuing Operations)': [13.356, -9.353], 'Selling, General, & Admin. Expense': [1.909, 1.76], 'Price to Tangible Book': [0.0, 6.07], 'Free Cashflow per Share': [0.007, 0.163], 'Cash Flow from Others': [-0.589, 1.166], 'Altman Z-Score': [1.75, 37.55], 'Depreciation, Depletion and Amortization': [0.078, 0.061], 'Shares Buyback Ratio (%)': [-0.01, 0.0], 'Market Cap': [0.0, 912.438], 'Cash, Cash Equivalents, Marketable Securities': [84.969, 161.932], 'Free Cash Flow': [0.398, 8.393], '  Change In Payables And Accrued Expense': [1.682, 0.213], 'Accounts Receivable': [16.171, 0.896], 'Net Margin %': [64.86, -682.82], 'Retained Earnings': [-34.889, -44.094], 'Total Assets': [106.531, 165.108], 'EV-to-EBIT': [0.0, -112.43], 'Cash Conversion Cycle': [71.66, 59.69], 'Common Stock': [1.019, 1.157], 'Current Ratio': [10.74, 14.5], '  Change In Prepaid Assets': [-1.115, 1.306], 'Shares Outstanding (Basic Average)': [55.396, 49.543], 'Price to Book': [0.0, 6.07], 'Change In Working Capital': [-12.461, 16.629], 'Return on Invested Capital %': [1986.14, 0.0], 'EBITDA per Share': [0.237, -0.159], 'Median PS (per share)': [13.39, 14.32], 'Cash Flow from Operations': [0.498, 8.707], 'Total Current Liabilities': [9.844, 11.315], 'EBIT per Share': [0.236, -0.161], 'Total Current Assets': [105.755, 164.08], 'EV-to-Revenue': [0.0, 32.95], '  Other Accrued Expense': [4.867, 6.954], 'Scaled Net Operating Assets': [0.112, -0.11], '   Interest Expense': [0.285, -1.09], 'Gross Profit': [20.592, 1.37], 'Net Current Asset Value (per share)': [1.67, 2.69], 'Earnings per Share (diluted)': [0.129, -0.185], 'EPS (Basic)': [0.129, -0.185], 'Fiscal Period': [201606.0, 201609.0], 'Net-Net Working Capital (per share)': [1.52, 2.67], 'Asset Turnover': [0.227, 0.01], 'Tangible Book per Share': [1.686, 2.712], 'Net Income': [13.356, -9.353], '  Cash And Cash Equivalents': [84.969, 161.932], 'Revenue per Share': [0.372, 0.027], 'Total Equity': [93.39, 150.235], 'Highest Stock Price': [0.0, 19.3], 'Cash Flow from Investing': [-0.1, -0.314], 'Net Change in Cash': [14.361, 78.368]}]